A NMR-Based Metabolomic Approach to Investigate the Antitumor Effects of the Novel [Pt(η 1-C2H4OMe)(DMSO)(phen)]+ (phen = 1,10-Phenanthroline) Compound on Neuroblastoma Cancer Cells

Federica De Castro; Erika Stefàno; Erik De Luca; Antonella Muscella; Santo Marsigliante; Michele Benedetti; Francesco Paolo Fanizzi

doi:10.1155/2022/8932137

A NMR-Based Metabolomic Approach to Investigate the Antitumor Effects of the Novel [Pt(η ¹-C₂H₄OMe)(DMSO)(phen)]⁺ (phen = 1,10-Phenanthroline) Compound on Neuroblastoma Cancer Cells

Bioinorg Chem Appl. 2022 Jun 10:2022:8932137. doi: 10.1155/2022/8932137. eCollection 2022.

Authors

Federica De Castro¹, Erika Stefàno¹, Erik De Luca¹, Antonella Muscella¹, Santo Marsigliante¹, Michele Benedetti¹, Francesco Paolo Fanizzi¹

Affiliation

¹ Department of Biological and Environmental Sciences and Technologies (DiSTeBA), University of Salento, Via Monteroni, I-73100 Lecce, Italy.

Abstract

NMR-based metabolomics is a very effective tool to assess the tumor response to drugs by providing insights for their mode of action. Recently, a novel Pt(II) complex, [Pt(ƞ¹-C₂H₄OMe)(DMSO)(phen)]⁺ (phen = 1,10-phenanthroline), Pt-EtOMeSOphen, was synthesized and studied for its antitumor activity against eight human cancer cell lines. Pt-EtOMeSOphen showed higher cytotoxic effects than cisplatin in most of the cancer cell lines and in particular against the neuroblastoma cell line (SH-SY5Y). In this study, the mechanism of action of Pt-EtOMeSOphen on SH-SY5Y cells was investigated using ¹H NMR-based metabolomics and compared with cisplatin. The observed time response of SH-SY5Y cells under treatment revealed a faster action of Pt-EtOMeSOphen compared with cisplatin, with a response already observed after six hours of exposure, suggesting a cytosolic target. NMR-based metabolomics demonstrated a peculiar alteration of the glutathione metabolism pathway and the diacylglycerol expression.